This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Beijing Strong Biotechnologies,Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Beijing Strong Biotechnologies,Inc. Announces Final Cash Dividend (Tax Included) (A Shares) for 2023, Payable on 07 May 2024 CI
Beijing Strong Biotechnologies,Inc. Proposes Final Cash Dividend for 2023 CI
Tranche Update on Beijing Strong Biotechnologies,Inc.'s Equity Buyback Plan announced on July 21, 2023. CI
Beijing Strong Biotechnologies,Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Tranche Update on Beijing Strong Biotechnologies,Inc.'s Equity Buyback Plan announced on July 21, 2023. CI
Tianfu Energy Chairman Proposes Buyback of Up to 30 Million Yuan Shares MT
Neo-Neon CFO Steps Down; Successor Named MT
ASIA COPPER WEEK-China to expand imports of scrap copper -industry association RE
Beijing Strong Biotechnologies,Inc. Reports Earnings Results for the Nine Months Ended September 30, 2023 CI
Tranche Update on Beijing Strong Biotechnologies,Inc.'s Equity Buyback Plan announced on July 21, 2023. CI
Beijing Strong Biotechnologies,Inc. Approves Executive Appointments CI
Beijing Strong Biotechnologies, Inc. Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Beijing Strong Biotechnologies, Inc. announces an Equity Buyback for CNY 80 million worth of its shares. CI
Beijing Strong Biotechnologies, Inc. authorizes a Buyback Plan. CI
Beijing Strong Biotechnologies, Inc. Announces Dividend on Share A for 2022, Payable on May 22, 2023 CI
Beijing Strong Biotechnologies, Inc. Approves Cash Dividend for 2022 CI
Beijing Strong Biotechnologies, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Beijing Strong Biotechnologies, Inc. Proposes Final Cash Dividend for the Year 2022 CI
Beijing Strong Biotechnologies, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Tranche Update on Beijing Strong Biotechnologies, Inc.'s Equity Buyback Plan announced on March 7, 2022. CI
Beijing Strong Biotechnologies, Inc.'s Equity Buyback announced on May 7, 2022, has expired with 2,867,000 shares, representing 0.49% for ¥50 million. CI
Beijing Strong Biotechnologies, Inc. Reports Earnings Results for the Nine Months Ended September 30, 2022 CI
Factbox-China's new political elites and their connection to Xi RE
'Alarm Bells' Ring as China Shuffles Economic Leaders at Critical Time MT
Chart Beijing Strong Biotechnologies,Inc.
More charts
Beijing Strong Biotechnologies Inc. is a China-based company mainly engaged in the research and development, manufacture and sales of in vitro diagnostic reagents. The Company’s in vitro diagnostic reagents are mainly used in liver, renal, blood fat, glycometabolism and other fields. The Company is also engaged in the manufacture and sales of in vitro diagnostic equipment and the leasing of equipment. The Company operates businesses in domestic and overseas markets.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
17.63
Average target price
-
Consensus

Annual profits - Rate of surprise

  1. Stock Market
  2. Equities
  3. 300406 Stock
  4. News Beijing Strong Biotechnologies,Inc.
  5. Beijing Strong Biotechnologies to Sell $170 Million Convertible RMB Bonds
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW